Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of...
19 insider purchases on record · latest filing 2026-03-31.
Insiders have also filed 122 sale transactions at MLYS.